The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
The once-popular DNA-testing site will also halt work on therapies it was developing.
Last year, the company said hackers had managed to gain access to personal information of millions of its users.
23andMe's share price has fallen by more than 70% this year, as its co-founder and chief executive Anne Wojcicki tries to turn the business around.
The company said it expected to incur one-off costs of $12m (£9.3m), including severance pay, for the plan that will result in savings of $35m.
"We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships," Ms Wojcicki said.